About D3

Background:

When medicines need to be taken for life, as for HIV infection, it is important that they not only work well, but also that they continue to be safe, with a low chance of long-term side effects, and that they are easy to take every day.

In D3, we aim to find out whether treating children and young people living with HIV with two anti-HIV medicines, dolutegravir and lamivudine, is safe and as effective as dolutegravir-based treatment with three anti-HIV medicines.

The study will include 370 children and young people aged 2 to less than 15 years old who are living with HIV and are being treated with anti-HIV medicines for the first time.

They will be split into two groups, by chance, by a process called “randomisation”.

• The first group will receive DTG-based three medicine treatment.

• The second group will change to the combination of two medicines, dolutegravir and lamivudine (with the combination written usually as “DTG/3TC”).

We will follow all children and young people until the last participant who joins the study has been in the study for 96 weeks.